If results are good and side effects manageable, theres no compelling reason to switch
Tirzepatide produced a significantly greater reduction in HbA1c compared to other OMMs, whereas liraglutide and semaglutide were associated with a greater reduction of FPG in contrast to the other OMMs (Table 1)
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Research suggests that 25% to 30% of weight lost on GLP-1 agonists can be lean mass rather than fat, particularly when protein intake is inadequate
To help overcome this limitation, our work focused on integrating data from multiple sources, including genetics, as well as complex signatures rather than individual proteins
A few of my favorite things we cover in this episode: Ozempic and emerging side effects